Imunon【IMNN】銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

0.841

買値

0.845

売値

0.8569

出来高

333,405

0.8027 日の範囲 0.894

0.48 52 週間の範囲 3.65

時価総額

12.195M

前日終値

0.899

始値

0.8787

時刻

0.8569

最終取引時間

財務取引量

US$ 283,108

VWAP

0.84914

平均取引量 (3 か月)

208,076

発行済株式数

14,500,685

配当利回り

PER

-0.62

1 株当たり利益 (EPS)

-1.35

歳入

純利益

-19.52M

Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to gen... Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. 詳細を表示

セクター

Pharmaceutical Preparations

業界

Health Care Diversified

ウェブサイト

www.imunon.com

本社

Dover, Delaware, USA

設立

1982

Imunon Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker IMNN. The last closing price for Imunon was US$0.90. Over the last year, Imunon shares have traded in a share price range of US$ 0.48 to US$ 3.65.

Imunon currently has 14,500,685 shares in issue. The market capitalisation of Imunon is US$13.04 million. Imunon has a price to earnings ratio (PE ratio) of -0.62.

IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001

Based on more than six months of additional monitoring, data show continued improvement in overall survival (OS) in intent-to-treat (ITT) population of women newly diagnosed with advanced ovarian...

Form 8-K - Current report

IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer

FDA Project Team supports the company’s proposed Phase 3 trial strategy, including overall trial design, target patient population, treatment schedule, and primary endpoint Final Protocol...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting

IMNN-001 immunotherapy plus standard-of-care chemotherapy resulted in 35% improvement in overall survival and 25% improvement in progression-free survival versus standard-of-care alone Treatment...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.019	-2.20930232558	0.86	0.9204	0.8202	199955	0.88369655	CS
4	0.042	5.25657071339	0.799	0.9204	0.64	201519	0.80503104	CS
12	-0.309	-26.8695652174	1.15	1.21	0.64	208076	0.91997506	CS
26	-0.319	-27.5	1.16	3.65	0.64	1572602	2.68884805	CS
52	-0.0001	-0.0118891927238	0.8411	3.65	0.48	860373	2.56755923	CS
156	-1.119	-57.0918367347	1.96	3.65	0.48	409069	2.50190577	CS
260	-1.119	-57.0918367347	1.96	3.65	0.48	409069	2.50190577	CS

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
LAESSEALSQ Corporation	US$ 1.1406 (99.75%)	225.46M
AMPGAmplitech Group Inc	US$ 1.9001 (91.52%)	201.88M
CADLCandel Therapeutics Inc	US$ 7.7401 (67.90%)	100.61M
JZXNJiuzi Holdings Inc	US$ 1.792 (60.00%)	2.56M
LDTCLeddarTech Holdings Inc	US$ 1.81 (49.59%)	75.14M
SFHGSamfine Creation Holdings Group Ltd	US$ 3.04 (-85.59%)	10.28M
CLRBCellectar Biosciences Inc	US$ 0.3039 (-76.26%)	38.21M
QTTBQ32 Bio Inc	US$ 6.0291 (-75.30%)	3.44M
TFFPTFF Pharmaceuticals Inc	US$ 0.1639 (-45.78%)	3.54M
MARXMars Acquisition Corporation	US$ 7.24 (-33.33%)	55.08k
RGTIRigetti Computing Inc	US$ 7.38 (13.71%)	313.25M
LAESSEALSQ Corporation	US$ 1.1406 (99.75%)	225.46M
AMPGAmplitech Group Inc	US$ 1.9001 (91.52%)	201.88M
NVDANVIDIA Corporation	US$ 139.31 (3.14%)	184.91M
LCIDLucid Group Inc	US$ 2.44 (3.39%)	111.23M